Current label evidence
Mounjaro and Zepbound report different grouped reaction data
The current Eli Lilly Mounjaro and Zepbound prescribing information was updated April 22, 2026. Mounjaro pooled placebo-controlled adult trials reported grouped injection-site reactions in 3.2% of treated adults and 0.4% of placebo-treated adults. Zepbound pooled adult weight-reduction trials reported grouped reactions in 6%, 8%, and 8% of patients receiving 5 mg, 10 mg, and 15 mg, respectively, versus 2% with placebo. The Zepbound group included bruising, redness, itching, pain, rash, and unspecified reaction. Different indications, populations, presentations, and study definitions make these context-specific figures—not a head-to-head comparison or one universal tirzepatide rate.
- Do not call 3.2%, 6%, or 8% a rate for redness, itching, pain, swelling, bruising, a lump, burning, infection, allergy, or any other single finding.
- Neither manufacturer label establishes one normal reaction size, onset, severity, cause, duration, or resolution cutoff.
- A grouped trial rate cannot diagnose one skin change or predict whether an individual reaction will recur.
Symptom and trend review
“Injection-site reaction” describes a location—not one diagnosis
A local reaction may be described as redness, itching, irritation, tenderness, warmth, pain, firmness, swelling, bruising, a lump, rash, or another change near the injection area. These findings can overlap with simple irritation, contact dermatitis, bleeding, infection, hypersensitivity, or tissue injury. A useful review focuses on timing and trend: when the change appeared, whether its border is stable or expanding, whether pain or warmth is increasing, whether it returns with later injections, and whether symptoms occur away from the site.
- Describe the border, approximate size, color change across your skin tone, warmth, pain, itching, firmness, swelling, bruising, drainage, red streaks, blistering, darkening, numbness, or breakdown rather than calling every finding a “rash.”
- Report fever, chills, feeling acutely unwell, facial or tongue swelling, throat tightness, breathing difficulty, dizziness, fainting, or widespread hives separately from the local skin change.
- A photo, percentage, or online checklist cannot rule out cellulitis, abscess, allergy, bleeding, tissue injury, or another condition when the pattern is concerning.
Exact-product identity
Match the reaction to Mounjaro, Zepbound, or the compounded prescription
Mounjaro and Zepbound contain tirzepatide but are separate FDA-approved finished drug products with different indications, presentations, instructions, and trial evidence. Current labels include presentation-specific pens, vials, multi-dose vials, and KwikPens. Mounjaro is labeled for adults and pediatric patients age 10 and older with type 2 diabetes, while Peptide12 provides adult care. A patient-specific compounded tirzepatide injection has its own prescription and pharmacy label. Product identity must be confirmed before label evidence or next-step guidance is applied.
- Record the exact product, indication context, route, strength or concentration, presentation, package or patient label, refill or lot, manufacturer or dispensing pharmacy, needle and supplies, shipment, and storage history.
- Tell the clinician whether the skin was already red, swollen, bruised, scarred, hardened, irritated, recently shaved, infected, or affected by eczema or another condition.
- Do not repeat, split, increase, retime, change routes, switch products, or use another injection as a test because a local reaction appeared.
Refill, supply, and exposure review
Changes around the skin or prescription may be relevant without proving a cause
A reaction review should include everything that touched the area and anything that changed with the prescription. Alcohol preparation, adhesive, bandages, cleansers, lotions, topical medicines, clothing friction, device or needle materials, caregiver assistance, a new refill, a concentration or presentation change, shipment conditions, or uncertain storage may be relevant. Timing can guide questions, but it does not prove medication allergy, pharmacy error, poor technique, or contamination.
- Share prior injection reactions, medication or adhesive allergies, anaphylaxis or angioedema, eczema or skin disease, diabetes, immune suppression, circulation problems, and bleeding risk.
- List blood thinners, antiplatelet medicines, immune-suppressing medicines, topical products, and every new prescription, over-the-counter medicine, or supplement.
- Preserve a damaged or confusing package and contact the responsible pharmacy or manufacturer rather than relying on seller chats, forums, copied syringe charts, or improvised device steps.
Compounded-product boundary
Branded reaction rates do not establish a compounded-tirzepatide rate
Mounjaro and Zepbound are FDA-approved finished drug products with manufacturer-controlled labeling. A patient-specific compounded tirzepatide preparation is not FDA-approved Mounjaro, Zepbound, or an FDA-approved generic finished product. It may differ in concentration, inactive ingredients, container, supplies, labeling, storage, and beyond-use date. Branded percentages cannot validate a compounded prescription, establish its local-reaction incidence, or explain one patient’s symptoms.
- For compounded tirzepatide, verify the patient label, active ingredient, concentration, route, dispensing pharmacy, inactive ingredients when available, supplies, storage, beyond-use date, refill details, and adverse-event contact.
- Ask the pharmacy about a changed label or concentration, particles, cloudiness, discoloration, damage, delayed or warm shipment, uncertain storage, or a different supply before another use decision.
- Avoid research-use vials, counterfeit pens, unlabeled syringes, copied unit conversions, no-prescription sellers, and claims that a skin reaction proves potency, purity, or absorption.
Escalation
Separate routine follow-up from allergy, infection, and tissue emergencies
A mild stable finding and a rapidly worsening reaction require different care paths. Persistent, recurrent, enlarging, worsening, unusually painful, or treatment-limiting symptoms deserve prescriber review even without an emergency feature. Rapidly spreading redness or swelling, increasing warmth or pain, pus, drainage, red streaks, fever, chills, blistering, darkening, numbness, skin breakdown, or feeling acutely unwell can require prompt local assessment. Breathing or throat symptoms, facial or tongue swelling, fainting, severe confusion, widespread hives, or a rapidly developing whole-body reaction can require emergency care.
- Use emergency services for breathing or throat symptoms, facial or tongue swelling, fainting, severe confusion, or a rapidly worsening widespread reaction.
- Seek prompt in-person assessment for rapid spread, severe or escalating pain, pus, streaking, fever or chills, blistering, darkening, numbness, or skin breakdown.
- Do not squeeze, puncture, vigorously massage, or use leftover antibiotics, prescription creams, antihistamines, steroids, or home remedies as a substitute for assessment.